![]() ![]() One of the most attractive medtech M&A targets, Conmed develops surgical and patient monitoring products and services, and most recently the company has gained traction in the surgical smoke management space, thanks to two successful business moves. We previously shared their insights on AtriCure, Haemonetics, NuVasive, LivaNova, and Globus Medical. Conmed was also among the most frequently asked about companies during those conversations, according to a report from Needham's Mike Matson, David Saxon, and Joseph Conway.Īt the time of the October 1 report, Needham had a hold recommendation on Conmed's stock, but the firm upgraded its recommendation to a buy on October 6. In recent weeks, Needham & Co.'s team of medtech analysts met with a series of investors across several regions of the United States.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |